AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01058902 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no aspirin
Description: nothing
Study NCT04218552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AD209
Description: PO, Once daily(QD), 8weeks
Study NCT01058902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no aspirin
Description: nothing
Study NCT04218552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine low
Description: PO, Once daily(QD), 8weeks
Study NCT04218552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine low
Description: PO, Once daily(QD), 8weeks
Study NCT04218552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine high
Description: PO, Once daily(QD), 8weeks
Study NCT04218552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine high
Description: PO, Once daily(QD), 8weeks
Study NCT04218552 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: PO, Once daily(QD), 8weeks
Study NCT04218552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Telmisartan
Description: PO, Once daily(QD), 8weeks
Study NCT02182466 — intervention group
Intervention type: DEVICE
Intervention: Colon capsule endoscopy
Study NCT04554992 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID 19 Convalescent Plasma
Description: COVID 19 convalescent plasma is a blood product collected from donors who have recovered from a previous COVID 19 infection
Study NCT00622804 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Billroth-II (B-II)
Description: After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.
Study NCT00622804 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux en Y gastrojejunostomy (RY-GJ)
Description: After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.
Study NCT00622804 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: uncut Roux en Y gastrojejunostomy
Description: After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
Study NCT02917824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity IMT
Description: 30 breaths at 50% of the maximal inspiratory pressure, twice daily for 6 weeks
Study NCT02917824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity IMT
Description: 30 breaths at 15% of the maximal inspiratory pressure, twice daily for 6 weeks
Study NCT01371877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D3
Description: Vitamin D 4000 IU per day for 3 months
Study NCT01371877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Vitamin D3
Description: Vitamin D 600 IU per day
Study NCT00936130 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic Roux-en-Y gastric bypass
Description: Laparoscopic Roux-en-Y gastric bypass surgery
Study NCT00936130 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic gastric banding
Description: Laparoscopic gastric banding surgery
Study NCT00936130 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Laparoscopic sleeve gastrectomy surgery
Study NCT00936130 — intervention group
Intervention type: BEHAVIORAL
Intervention: Low Calorie Diet
Description: Low Calorie Diet Program
Study NCT01343667 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gore Flow Reversal System
Description: Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting
Study NCT01343667 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gore Embolic Filter
Description: Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting
Study NCT00532272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole ,Goserelin
Description: Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
Study NCT00532272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole ,Goserelin
Description: Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
Study NCT02232152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study NCT02232152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT02232152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02232152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00503997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy.
Study NCT00503997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.~Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy.
Study NCT01131039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Bevacizumab
Description: Gemcitabine: IV, days 1,8, and every 21 days~Bevacizumab: IV, day 1 and every 21 days until disease progression
Study NCT03410732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: activated DCs
Description: autologous dendritic cells are collected and enriched from 50 ml of peripheral blood, then activated by autologous tumor cell membrane proteins. Then the activated DCs are iv infused in 21 days after a radical surgery.
Study NCT03410732 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical surgery only
Description: Only radical surgery is given to the control group
Study NCT03410732 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical surgery only
Description: Only radical surgery is given to the control group
Study NCT00844480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: zoledronic acid, 5mg, iv
Study NCT00844480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: iv
Study NCT01700738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric ring surgery
Study NCT01700738 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nutritional help
Study NCT03729414 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mucopexy with Doppler artery ligation
Description: Hemorrhoids will be treated by mucopexy with Doppler guided hemorrhoids arteries ligation performed in all quadrants
Study NCT03729414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mucopexy without Doppler artery ligation
Description: Hemorrhoids will be treated by mucopexy alone performed in all quadrants
Study NCT02906033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New perioperative practice model
Description: The one and same anesthesia nurse takes care of the patient during the entire perioperative process and even pays the patient a visit to the ward the day after surgery.
Study NCT01286194 — intervention group
Intervention type: DRUG
Intervention: Rabeprazole sodium
Description: Rabeprazole sodium 10 mg orally every day for 14 days
Study NCT01923844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exogenous surfactant
Description: Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached > 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
Study NCT02071082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
Study NCT03619824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg ivdrip, every 3 weeks for 6 cycles
Study NCT03619824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1g/m2, d1 \& 8 of every cycle, every 3 weeks for 3 cycles before radiation.
Study NCT03619824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Induction cisplatin 80mg/m2, every 3 weeks for 3 cycles before radiation Concurrent cisplatin 100mg/m2, every 3 weeks for 2 cycles during radiation
Study NCT03619824 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: Definitive IMRT of 66-70Gy will be given in six to seven weeks.
Study NCT00691639 — intervention group
Intervention type: OTHER
Intervention: Blood Collection Only
Description: Blood Collection Only
Study NCT01069237 — intervention group
Intervention type: DEVICE
Intervention: OPTI-FREE RepleniSH
Description: Multi-Purpose Solution for soft contact lenses
Study NCT01069237 — intervention group
Intervention type: DEVICE
Intervention: Clear Care
Description: Lens Care Solution for contact lenses
Study NCT04796883 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hanita Glaucoma shunt Ver.3.2
Description: The procedure will be performed under anesthesia (at physician discretion) and a Hanita shunt devce will be implanted.
Study NCT01474031 — intervention group
Intervention type: OTHER
Intervention: Biomechanics
Description: * Time interval: pre-op - 3m - 6m - 12m~* Assessment of all subjects:~  * XR~ * Gait analysis with surface EMG and trunk markers:~    * Unipodal standing: 3 trials Right and 3 trials Left on FP~   * Level walking: 3 trials Right and 3 trials Left on FP~   * Chair rise: 3 trials, both legs on FP~   * Stair ascent: 3 trials Right and 3 trials Left on first FP~   * Stair descent: 3 trials Right and 3 trials Left on first FP~   * Squat: 3 trials, both legs on FP~ * Bipodal squat: 3 trials Right and 3 trials Left on FP~* Functional scores (HHS, UCLA, HOOS, SF-36)
Study NCT01276691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 81 mg enteric coated aspirin
Description: 81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
Study NCT01276691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 81 mg enteric coated aspirin
Description: 81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
Study NCT00394771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-1031
Description: Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
Study NCT00394771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seasonale®
Description: 84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
Study NCT00394771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Portia®
Description: Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
Study NCT00394771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Portia®
Description: Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
Study NCT04236167 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser treatment -
Description: UltraPulse CO2 Laser (Lumenis, Israel). Patients will receive laser treatments at 4 to 8-week intervals for a total of 3 sessions. A combination of the SCAAR FX and Deep FX treatment modes, with or without Active FX treatment mode, will be used according to individual patient and scar characteristics. For SCAAR FX, the settings include energy (70-150mJ), density (1-5%), and frequency (150-250Hz).For Deep FX, the settings include energy (12.5-22.5mJ), density (5-15%) and frequency (300-600Hz). For Active FX, the settings include energy (80-125mJ), density (2-3%) and frequency (100-150Hz)
Study NCT01116713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous dexamethasone
Description: One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.
Study NCT01116713 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Homologated placebo.
Description: Patients of the control group received homologated placebo 60 minutes before skin incision
Study NCT01315041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsicum frutescens fruits, homeopathic medicine
Description: 5 drops, PO, 3 times a day, during 16 weeks
Study NCT01315041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inert alcoholic solution
Description: 5 drops, PO, 3 times a day, during 16 weeks
Study NCT01592292 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Rituximab as per physician's discretion.
Study NCT01592292 — intervention group
Intervention type: DRUG
Intervention: Adalimumab
Description: Adalimumab as per physician's discretion.
Study NCT01592292 — intervention group
Intervention type: DRUG
Intervention: Etanercept
Description: Etanercept as per physician's discretion.
Study NCT01592292 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: Infliximab as per physician's discretion.
Study NCT03564080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined - PAD and CAD
Description: 12-week supervised exercise programme in a hospital setting
Study NCT01783821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).
Study NCT01783821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
Study NCT01783821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .
Study NCT04028622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TCAD (telemedicine anesthesia consultation)
Description: Patients in the TCAD (telemedicine anesthesia consultation) group, arrange their bookings on a website and realise their anesthesia consultation from a platform from home
Study NCT02332239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iDOVE Intervention (ED+text)
Description: 1. In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention~2. Eight-week longitudinal tailored text-message program
Study NCT02332239 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control (EUC)
Description: 1. In-ED brief session, discussing home safety \& nutrition~2. Eight-week longitudinal home safety \& nutrition text-message program
Study NCT03433313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG12014
Description: EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
Study NCT03433313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
Study NCT02764567 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Oil
Description: Participants in this arm will be offered one of three essential oils: ginger, lavender or calming
Study NCT03059199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single-Arm Feasibility Study
Description: Participants are provided with the HAT TRICK Playbook, a resource manual including weekly healthy eating and physical activity challenges and tracking logs. Each face-to-face session is facilitated by trained research staff, community partners, and health care professionals. Weekly sessions include information on physical activity, healthy eating, and behaviour change techniques (e.g., social support, goal setting, self-monitoring) and include an opportunity to be active/exercise.
Study NCT01576003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 days (6 months)
Study NCT01576003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-alanine
Description: 0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 day (6 months)
Study NCT02870205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSP 301 NS
Description: 2 spray in each nostril twice daily for 14 days
Study NCT02870205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GOM-NS
Description: 2 spray in each nostril twice daily for 14 days
Study NCT02870205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GMM-2 NS
Description: 2 spray in each nostril twice daily for 14 days
Study NCT02870205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSP 301 placebo NS
Description: 2 spray in each nostril twice daily for 14 days
Study NCT04520581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group O
Description: Endotracheal tube was made O shape by assistants.
Study NCT03248414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus sakei
Description: 1 pack contained 5 x 109 cfu
Study NCT00887380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-radiotherapy commencement of anastrozole
Description: Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.
Study NCT00887380 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
Study NCT03248414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus sakei
Description: 1 pack contained 5 x 109 cfu
Study NCT03449394 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metacognitive Training
Description: 4 sessions of Metacognitive Training using 4 treatment modules each targeting different cognitive biases